Mark J. Suto

3.5k citations

88 papers · 2.6k indexed · h-index 30

Molecular Biology top 5%
- Cancer therapeutics and mechanisms 8
- Chemical Synthesis and Analysis 8
- RNA Interference and Gene Delivery 4
Cancer Research top 5%
- NF-κB Signaling Pathways 7
Organic Chemistry top 5%
- Synthesis and Biological Evaluation 6
- Synthesis and biological activity 5
- Synthetic Organic Chemistry Methods 4
Oncology top 5%
- Cytokine Signaling Pathways and Interactions 5
Physiology top 5%

Co-authors: Joanne E. Murphy-Ullrich Yonghe Li Taj D. King William R. Turner Wei Zhang Judith S. Sebolt–Leopold Indira Padmalayam Moorthy S. S. Palanki
Cited by: Molecular Biology Cancer Research Organic Chemistry
Journals: Journal of Medicinal Chemistry (13 papers)Tetrahedron Letters (6 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)
Partner nations: United States Japan China

In The Last Decade

Mark J. Suto

87 papers receiving 2.4k citations

Peers

Countries citing papers authored by Mark J. Suto

Since Specialization

Citations

This map shows the geographic impact of Mark J. Suto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Suto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Suto more than expected).

Fields of papers citing papers by Mark J. Suto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Suto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Suto. The network helps show where Mark J. Suto may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark J. Suto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Suto Line = papers co-authored together Mark J. Suto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series New Microbes and New Infections ·Shuichi Abe,Dhammika Leshan Wannigama,Yu Suzuki,Mabel Tirado Espinosa,Jun Igarashi,Mark J. Suto,Kyoji Moriya,Muhammad Zerq Elvonda Graha Yuda,Yusuke Okuma,Parichart Hongsing,Cameron Hurst,Thammakorn Saethang,Paul G. Higgins,Stephen M. Stick,Anthony Kicic	2024	2
2	Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability Neurotherapeutics ·Cláudia Maria Canestrine do Nascimento Bernardi,Travis Rush,阿里路呀,Yannete Esquivel,Siti Hediati Rahminita,ANTONIO REYES-BELTRAN,J. Nicholas Cochran,Marvyn O'Rourke,A.J. Walker,Zhengrong Yang,Vibha Pathak,P.M. Lebedev,Miriam Elizabeth Merino Peñafiel,Jeremy J. Day,J. Robert Bostwick,Mark J. Suto,Corinne E. Augelli‐Szafran,Erik D. Roberson	2023	6
3	Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals Bioorganic & Medicinal Chemistry Letters ·Farhan Shaikh,Bini Mathew,Ritesh K. Srivastava,Jasim Khan,Suhail Muzaffar,Sixue Zhang,Miriam Elizabeth Merino Peñafiel,Ling Zhai,P.M. Lebedev,Anupam Agarwal,J. Robert Bostwick,Mark J. Suto,Mohammad Athar,Corinne E. Augelli‐Szafran	2022	5
4	Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow Molecular Cancer Therapeutics ·Chao Zhang,Xiaoxuan Xu,Timothy N. Trotter,Pramod S. Gowda,Yun Lü,Mark J. Suto,Amjad Javed,Joanne E. Murphy-Ullrich,Juan Li,Laya Vercauteren	2021	6
5	HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007) Advances in Virology ·Raj Kalkeri,Kristin Krumenacker,Vaishali Bhagat,Zhaohui Cai,Roger G. Ptak,Mark J. Suto	2020	4
6	Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β ACS Medicinal Chemistry Letters ·Mark J. Suto,G Holodnyy,Bini Mathew,Wei Zhang,Manuel A. Pallero,Joanne E. Murphy-Ullrich	2020	15
7	Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS European Journal of Medicinal Chemistry ·Bini Mathew,P.M. Lebedev,Shilpa Dutta,A D Katsen,Sixue Zhang,Literatura Franco,Micah Simmons,Corinne E. Augelli‐Szafran,Rita M. Cowell,Mark J. Suto	2020	7
8	Development of novel small molecules for the treatment of ALS Bioorganic & Medicinal Chemistry Letters ·Bini Mathew,P.M. Lebedev,Vibha Pathak,Mark J. Suto	2020	8
9	Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics PLoS ONE ·Lucas Weinberg,Chamali Gajaweera,Ana Paula Alencar Moura,John T. Piazza,Y. S. Gasimov,Kanupriya Whig,Ling Zhai,尚子内,Frank Chlebana,M Li,秀彦高良,Dimitris Komiotis,Christopher P. Mill,A Muggia,Forrest Smith,Mark J. Suto,Robert Bostwick,Ram B. Gupta,Allan E. David,David J. Riese	2020	2
10	Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease Matrix Biology ·Joanne E. Murphy-Ullrich,Mark J. Suto	2017	233
11	Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma American Journal Of Pathology ·Ailing Lu,Manuel A. Pallero,Weiqi Lei,Huixian Hong,Yang Yang,Mark J. Suto,Joanne E. Murphy-Ullrich	2016	49
12	Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations American Journal of Respiratory and Critical Care Medicine ·Venkateshwar Mutyam,Ming Du,B Serbes,Kim M. Keeling,E. Lucile White,J. Robert Bostwick,Lynn Rasmussen,Bo Liu,Marina Mazur,Jeong S. Hong,Emily Falk Libby,Feng Liang,박해정,Martin Mense,Mark J. Suto,David M. Bedwell,Steven M. Rowe	2016	63
13	First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors Annals of Oncology ·Geraldine O’Sullivan Coyne,静香中路,Shivaani Kummar,Jerry M. Collins,Robert Meehan,Mark J. Suto,Larry Rubinstein,Robert J. Kinders,Nicole M. Moore,Ralph E. Parchment,Yvonne Horneffer,Lamin Juwara,Michael J. Difilippantonio,Richard Piekarz,James H. Doroshow	2016	4
14	AlphaScreen HTS and Live-Cell Bioluminescence Resonance Energy Transfer (BRET) Assays for Identification of Tau–Fyn SH3 Interaction Inhibitors for Alzheimer Disease SLAS DISCOVERY ·J. Nicholas Cochran,Gaoqiang Wang,김용성,Lynn Rasmussen,E. Lucile White,Robert Bostwick,Joseph A. Maddry,Mark J. Suto,Erik D. Roberson	2014	18
15	Frizzled7 as an emerging target for cancer therapy Cellular Signalling ·Taj D. King,Wei Zhang,Mark J. Suto,Yonghe Li	2011	118
16	The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies Bioorganic & Medicinal Chemistry Letters ·Moorthy S. S. Palanki,Paul Erdman,Wei Dou,Mark J. Suto,Brydon L. Bennett,Anthony M. Manning,Lynn J. Ransone,Styliani Ioannidou,Sonal J. Desai,Mika KOYAMA,胡显明,Peter Tsao,Wataru Toriumi	2003	32
17	SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo. PubMed ·Mark E. Goldman,Lynn J. Ransone,David W. Anderson,William A. Gaarde,Mark J. Suto,Robert W. Sullivan,R. Shorthouse,Masayuki Morikawa,Randal E. Morris	1996	11
18	High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone / naphthyridone antibacterials Mutation Research/Genetic Toxicology ·Victor Ciaravino,Mark J. Suto,Jeffrey C. Theiss	1993	22
19	A new class of analog of the bifunctional radiosensitizer .alpha.-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines Journal of Medicinal Chemistry ·Mark J. Suto,Michael A. Stier,Leslie M. Werbel,SWETHA RANI AITHA,Wilbur R. Leopold,Cheng'en Zheng,Judith S. Sebolt–Leopold	1991	6
20	1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach Journal of Medicinal Chemistry ·Robert A. Coburn,Eva Wilcox,Mark J. Suto,A. J. Solo,A. M. Triggle,David J. Triggle	1988	113

About Mark J. Suto

Mark J. Suto is a scholar working on Cancer Research, Organic Chemistry, Molecular Biology, Oncology and Physiology, having authored 88 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (8 papers), Chemical Synthesis and Analysis (8 papers), NF-κB Signaling Pathways (7 papers), Synthesis and Biological Evaluation (6 papers), Synthesis and biological activity (5 papers), Cytokine Signaling Pathways and Interactions (5 papers), RNA Interference and Gene Delivery (4 papers) and Synthetic Organic Chemistry Methods (4 papers). The work is most often cited by research in Molecular Biology (1.5k citations), Cancer Research (320 citations), Organic Chemistry (564 citations), Oncology (531 citations) and Physiology (61 citations). Mark J. Suto has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Joanne E. Murphy-Ullrich, Yonghe Li, Taj D. King, William R. Turner, Wei Zhang, Judith S. Sebolt–Leopold, Indira Padmalayam, Moorthy S. S. Palanki, Lynn J. Ransone and A. J. Solo. Their work appears in journals such as Journal of Medicinal Chemistry, Tetrahedron Letters, Bioorganic & Medicinal Chemistry Letters, Oncotarget and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact